Left atrial appendage closure

Inder M. Singh, David Holmes

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Stroke prevention is the primary goal in atrial fibrillation (AF) given its clinical and socioeconomic impact. With AF, the prevalence of thromboembolic stroke continues to rise and there is an urgent need to develop better strategies of stroke prevention. Warfarin, although effective when used appropriately, is burdened by underutilization, narrow therapeutic windows, and life-threatening bleeding complications. Novel pharmacologic agents have been plagued by off-target toxicity and only modest improvement in bleeding complications over warfarin. Because most thromboemboli arise from the left atrial appendage (LAA), surgical exclusion of the LAA is often used in AF patients undergoing cardiac surgery. Percutaneous device LAA closure has now been developed as an adjunct and as an alternative to pharmacotherapy in patients with AF. Promising randomized data are available with the WATCHMAN device, while several other devices are in various stages of clinical and preclinical development.

Original languageEnglish (US)
Pages (from-to)413-421
Number of pages9
JournalCurrent cardiology reports
Volume12
Issue number5
DOIs
StatePublished - Sep 1 2010

Fingerprint

Atrial Appendage
Atrial Fibrillation
Stroke
Warfarin
Equipment and Supplies
Hemorrhage
Primary Prevention
Thoracic Surgery
Drug Therapy
Therapeutics

Keywords

  • Atrial fibrillation
  • Left atrial appendage
  • Percutaneous closure
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Left atrial appendage closure. / Singh, Inder M.; Holmes, David.

In: Current cardiology reports, Vol. 12, No. 5, 01.09.2010, p. 413-421.

Research output: Contribution to journalReview article

Singh, Inder M. ; Holmes, David. / Left atrial appendage closure. In: Current cardiology reports. 2010 ; Vol. 12, No. 5. pp. 413-421.
@article{9b482ce633c14cf588d30ab657856e89,
title = "Left atrial appendage closure",
abstract = "Stroke prevention is the primary goal in atrial fibrillation (AF) given its clinical and socioeconomic impact. With AF, the prevalence of thromboembolic stroke continues to rise and there is an urgent need to develop better strategies of stroke prevention. Warfarin, although effective when used appropriately, is burdened by underutilization, narrow therapeutic windows, and life-threatening bleeding complications. Novel pharmacologic agents have been plagued by off-target toxicity and only modest improvement in bleeding complications over warfarin. Because most thromboemboli arise from the left atrial appendage (LAA), surgical exclusion of the LAA is often used in AF patients undergoing cardiac surgery. Percutaneous device LAA closure has now been developed as an adjunct and as an alternative to pharmacotherapy in patients with AF. Promising randomized data are available with the WATCHMAN device, while several other devices are in various stages of clinical and preclinical development.",
keywords = "Atrial fibrillation, Left atrial appendage, Percutaneous closure, Stroke",
author = "Singh, {Inder M.} and David Holmes",
year = "2010",
month = "9",
day = "1",
doi = "10.1007/s11886-010-0122-9",
language = "English (US)",
volume = "12",
pages = "413--421",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "5",

}

TY - JOUR

T1 - Left atrial appendage closure

AU - Singh, Inder M.

AU - Holmes, David

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Stroke prevention is the primary goal in atrial fibrillation (AF) given its clinical and socioeconomic impact. With AF, the prevalence of thromboembolic stroke continues to rise and there is an urgent need to develop better strategies of stroke prevention. Warfarin, although effective when used appropriately, is burdened by underutilization, narrow therapeutic windows, and life-threatening bleeding complications. Novel pharmacologic agents have been plagued by off-target toxicity and only modest improvement in bleeding complications over warfarin. Because most thromboemboli arise from the left atrial appendage (LAA), surgical exclusion of the LAA is often used in AF patients undergoing cardiac surgery. Percutaneous device LAA closure has now been developed as an adjunct and as an alternative to pharmacotherapy in patients with AF. Promising randomized data are available with the WATCHMAN device, while several other devices are in various stages of clinical and preclinical development.

AB - Stroke prevention is the primary goal in atrial fibrillation (AF) given its clinical and socioeconomic impact. With AF, the prevalence of thromboembolic stroke continues to rise and there is an urgent need to develop better strategies of stroke prevention. Warfarin, although effective when used appropriately, is burdened by underutilization, narrow therapeutic windows, and life-threatening bleeding complications. Novel pharmacologic agents have been plagued by off-target toxicity and only modest improvement in bleeding complications over warfarin. Because most thromboemboli arise from the left atrial appendage (LAA), surgical exclusion of the LAA is often used in AF patients undergoing cardiac surgery. Percutaneous device LAA closure has now been developed as an adjunct and as an alternative to pharmacotherapy in patients with AF. Promising randomized data are available with the WATCHMAN device, while several other devices are in various stages of clinical and preclinical development.

KW - Atrial fibrillation

KW - Left atrial appendage

KW - Percutaneous closure

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=77956267129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956267129&partnerID=8YFLogxK

U2 - 10.1007/s11886-010-0122-9

DO - 10.1007/s11886-010-0122-9

M3 - Review article

C2 - 20544311

AN - SCOPUS:77956267129

VL - 12

SP - 413

EP - 421

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 5

ER -